The purpose of this work is to verify the implementation of methods and techniques of analysis performed on the final product to comply with the requirements established by DIGEMID and OTAN. The personnel involved in the production of these radiopharmaceuticals are exposed to radiation, so the doses received by the POE must be monitored so that the limits established by OTAN are not exceeded. In the present study, analytical tests based on chromatographic methods (HPLC, TLC and GC) will be carried out on 18F-FDG obtained during the commissioning of the Thymoteo synthesis module, which performs synthesis by basic hydrolysis. Results were obtained that proved the integrity of the purification system coupled to the module, obtaining the final product with high purity, identity and integrity. The production processes and quality controls developed by the personnel involve the handling of open sources of positron emitters, which implies that they are exposed to radiation doses. The monthly evaluation required by OTAN of the doses received by the POE of the PET radiopharmacy service of the Radiopharmaceutical Production Center is carried out with the use of a TLD Dosimetry System, provided by the radioprotection officer. IAEA TECDOC 1731 refers to the radioprotection implications of the new dose limit for occupationally exposed personnel. Based on this document, characterization measurements of OSLD nanoDots and EPD dosimetric systems on anthropomorphic head and torso phantom were performed as potential alternatives to the goggle-mounted ring TLDs evaluated in previous work in PET radiopharmacy at the Radiopharmaceutical Production Center. Meanwhile, OSL dosimeters present adequate reproducibility for dosimetry. It is suggested that the use of both dosimetric systems in a complementary way is useful to develop routine monitoring of whole-body equivalent doses. In addition, from the point of view of Medical Physics, the urgent need for particle accelerators with more energy and facilities for the development of Science and Technology in the country can be confirmed. Likewise, the ESSALUD facility has a 16.5 Mev cyclotron, with a proton flux of 60 µA, the possibility of dual B irradiation for the 18F-Fluoride target 18FH Carbon target, nitrogen-ammonia target 13NH3. Based on the results obtained during the year 2021, it can be concluded that the activities of the Radiopharmaceutical Production Center do not cause any radiological impact on the population and the environment

Quality Controls, Pettrace 800 Cyclotron, POE, EPD, OSL, TLD.